N/A N=392 Innovative Approach in Tuberculosis Care in Armenia
Tuberculosis
Primary: TB Treatment Success Rates Defined by the World Health Organization (WHO) — 184; 176 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
Leukemia
Primary: Overall Response Rate (ORR) — 0; 3 Participants
Phase 2 N=51 INCB018424 in Patients With Advanced Hematologic Malignancies
Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myelodysplastic Syndrome
Primary: Response Rate — 7 Participants
Phase 3 N=16 Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
Glaucoma, Neovascular
Primary: Change in Intraocular Pressure (IOP) From Baseline to Week 1 — -8.3 mmHg — p=0.0004
Phase 3 N=560 Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
Diabetes Mellitus, Type 1
Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year
N/A N=36 Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion
Degenerative Changes · Stenosis · Spondylosis
Primary: Time to Arthrodesis (Fusion) for Each Spinal Level (Unit), as Measured by X-rays. — 6 months to fusion
N/A N=151 Evaluating the Safety of PregSense™ and Compare Its Performance to CTG in Prenatal Monitoring of Pregnant Subjects
Pregnancy
Primary: Fetal Heart Rate — 140.3; 140.4 bpm
Phase 2 N=15 A Study of Oxidative Pathways in MS Fatigue
Progressive Multiple Sclerosis · Fatigue
Primary: Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine. — 12; 6 adverse events
Phase 2 N=18 The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia
Paranoia · Schizophrenia-spectrum Diagnosis
Primary: Green Paranoid Thoughts Scale (GPTS) — 109.77; 114.6; 84.8; 82.6 score on a scale
N/A N=31 Physical Activity Behavior Change for Older Adults After Dysvascular Amputation
Amputation · Diabetes Mellitus, Type 2 · Peripheral Artery Disease
Primary: Retention Rate — 14; 13 Participants
Phase 2 N=30 Neoadjuvant Pembrolizumab
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
N/A N=33 Clinical Biocompatibility Evaluation of Contact Lens Coatings
Refractive Errors · Ametropia
Primary: Average Percent Area of Solution-related Corneal Staining — 7.01; 12.82; 13.54; 7.58 percentage of area
Phase 2 N=34 Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas
Adenocarcinoma of the Pancreas
Primary: Maximum Tolerated Dose (MTD) of AZD1775 (MK-1775) When Used Concurrently With Gemcitabine and Radiation Therapy. — 150 mg
Phase 2 N=48 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Phase 3 N=55 Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age
Moderate to Severe Convexity of Submental Fat · Safety · Efficacy
Primary: Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating…